ASA reduced VTE risk

In this large multi center study, patients with an unprovoked VTE who had already completed 6-18 months of anticoagulation were randomized to ASA 100mg/day or placebo for 2 years. The risk of recurrent VTE was 11% in the placebo group and 7% in the ASA group (hazard ratio 0.58, CI 0.36 to 0.93), with no difference between groups in bleeding or adverse events. This should change current practice, and promote long term use low dose ASA after initial anticoagulation in patients with unprovoked VTE (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment